Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab.
Pembrolizumab
immunotherapy
nivolumab
non-small-cell lung cancer
post-progression survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
26
3
2021
Statut:
ppublish
Résumé
Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, clinical characteristics that predicted receipt of st after PD1 Ab failure were evaluated. All patients with ansclc in British Columbia initiated on nivolumab or pembrolizumab between June 2015 and November 2017, with subsequent progression, were identified. Eligibility criteria for additional st included an Eastern Cooperative Oncology Group (ecog) performance status (ps) of 3 or less and survival for more than 30 days from the last PD1 Ab treatment. Post-progression survival (pps) was assessed by landmark analysis. Baseline characteristics associated with pps were identified by multivariable analysis. Of 94 patients meeting the eligibility criteria, 33 received st after progression. In 75.6%, a PD1 Ab was received as first- or second-line treatment. The most common sts were erlotinib (36.4%) and docetaxel (27.3%). No statistically significant difference in median pps was observed between patients who did and did not receive st within 30 days of their last PD1 Ab treatment (6.9 months vs. 3.6 months, log-rank In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments.
Sections du résumé
Background
Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, clinical characteristics that predicted receipt of st after PD1 Ab failure were evaluated.
Methods
All patients with ansclc in British Columbia initiated on nivolumab or pembrolizumab between June 2015 and November 2017, with subsequent progression, were identified. Eligibility criteria for additional st included an Eastern Cooperative Oncology Group (ecog) performance status (ps) of 3 or less and survival for more than 30 days from the last PD1 Ab treatment. Post-progression survival (pps) was assessed by landmark analysis. Baseline characteristics associated with pps were identified by multivariable analysis.
Results
Of 94 patients meeting the eligibility criteria, 33 received st after progression. In 75.6%, a PD1 Ab was received as first- or second-line treatment. The most common sts were erlotinib (36.4%) and docetaxel (27.3%). No statistically significant difference in median pps was observed between patients who did and did not receive st within 30 days of their last PD1 Ab treatment (6.9 months vs. 3.6 months, log-rank
Conclusions
In this cohort, only 35.1% of patients eligible for post-PD1 Ab therapy received st. Post-progression survival was not significantly affected by receipt of post-progression therapy. Prospective trials are needed to clarify the benefit of post-PD1 Ab treatments.
Identifiants
pubmed: 32489249
doi: 10.3747/co.27.5495
pii: conc-27-76
pmc: PMC7253749
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Nivolumab
31YO63LBSN
pembrolizumab
DPT0O3T46P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-82Informations de copyright
2020 Multimed Inc.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
Références
N Engl J Med. 2005 Jul 14;353(2):123-32
pubmed: 16014882
J Clin Oncol. 2013 Mar 10;31(8):1061-9
pubmed: 23401452
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
J Thorac Oncol. 2018 Jul;13(7):978-986
pubmed: 29738824
PLoS One. 2018 Aug 28;13(8):e0203070
pubmed: 30153300
Lung Cancer. 2019 Aug;134:127-140
pubmed: 31319971
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2014 Jun 20;32(18):1902-8
pubmed: 24841974
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Clin Oncol. 2004 May 1;22(9):1589-97
pubmed: 15117980
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
J Exp Med. 2007 Jan 22;204(1):49-55
pubmed: 17210731
J Clin Oncol. 2005 Apr 1;23(10):2346-57
pubmed: 15800326
Lancet Oncol. 2013 Sep;14(10):981-8
pubmed: 23883922
J Clin Oncol. 2008 Sep 10;26(26):4268-75
pubmed: 18626007
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):363-71
pubmed: 21586725
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Lancet Oncol. 2010 Jun;11(6):521-9
pubmed: 20493771
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Lung Cancer. 2017 Oct;112:90-95
pubmed: 29191606
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465